CoChat
Sign Up
Cited by 2,426

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Renal cell carcinoma

Hsieh, James J., Purdue, Mark P., Signoretti, Sabina, Swanton, Charles, Albiges, Laurence, Schmidinger, Manuela, Heng, Daniel Y., Larkin, James, Ficarra, Vincenzo·2017·Nature Reviews Disease Primers
DOI 10.1038/nrdp.2017.9PMC PMC5936048
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrdp.2017.9

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 16 references

Research works printed but not linked: 193

  1. Eble, J. N., Sauter, G., Epstein, J. I. & Sesterhenn, I. A. (eds) World Health Organization Classification Of Tumours (IARC Press, 2004).
  2. Kovacs, G. et al. The Heidelberg classification of renal cell tumours. J. Pathol. 183, 131–133 (1997). This is the first consensus classification of RCC. · DOI
  3. Lopez-Beltran, A., Scarpelli, M., Montironi, R. & Kirkali, Z. 2004 WHO classification of the renal tumors of the adults. Eur. Urol. 49, 798–805 (2006). · DOI
  4. Srigley, J. R. et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am. J. Surg. Pathol. 37, 1469–1489 (2013). · DOI
  5. Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E. & Ulbright, T. M. The 2016 WHO classification of tumours of the urinary system and male genital organs — part A: renal, penile, and testicular tumours. Eur. Urol. 70, 93–105 (2016). This is the current consensus on RCC classification. · DOI
  6. Chen, F. J. et al. Multilevel genomics-based taxonomy of renal cell carcinoma. Cell Rep. 14, 2476–2489 (2016). This is a comprehensive genomic analysis of three major RCC subtypes (KIRC, KICH and KIRP), characterized by The Cancer Genome Atlas kidney cancer working groups. · DOI
  7. Davis, C. F. et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26, 319–330 (2014). · DOI
  8. Chen, Y. B. et al. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nat. Commun. 7, 13131 (2016). · DOI
  9. Rini, B. I., Campbell, S. C. & Escudier, B. Renal cell carcinoma. Lancet 373, 1119–1132 (2009). · DOI
  10. Vera-Badillo, F. E. et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur. Urol. 67, 740–749 (2015). · DOI
  11. Kroeger, N. et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 119, 2999–3006 (2013). · DOI
  12. Escudier, B. et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27, v58–v68 (2016). · DOI
  13. Motzer, R. J. et al. Kidney cancer, version 3. 2015. J. Natl Compr. Canc. Netw. 13, 151–159 (2015). · DOI
  14. Sankin, A., Hakimi, A. A., Hsieh, J. J. & Molina, A. M. Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies. Front. Oncol. 5, 67 (2015). · DOI
  15. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014). · DOI
  16. Sankin, A. et al. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Med. 3, 1485–1492 (2014). · DOI
  17. Hsieh, J. J. et al. Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma. Eur. Urol. 71, 405–414 (2017). This paper reports on the prevalent mutations in metastatic ccRCC tumours and the prognostic and predictive values of molecular classification of ccRCC based on genomic mutations in patients treated with targeted therapies in a randomized trial. · DOI
  18. Molina, A. M. et al. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur. J. Cancer 50, 351–358 (2014). · DOI
  19. Motzer, R. J. et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 32, 2765–2772 (2014). · DOI
  20. Hsieh, J. J. et al. Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: a braided cancer river model of kidney cancer. Semin. Cell Dev. Biol.http://dx.doi.org/10.1016/j.semcdb.2016.09.002 (2016). · DOI
  21. Ljungberg, B. et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur. Urol. 67, 913–924 (2015). · DOI
  22. El Dib, R., Touma, N. J. & Kapoor, A. Cryoablation versus radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. BJU Int. 110, 510–516 (2012). · DOI
  23. Pierorazio, P. M. et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur. Urol. 68, 408–415 (2015). · DOI
  24. Frank, I. et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168, 2395–2400 (2002). This paper reports on the first commonly employed outcome prediction model (SSIGN) for patients with localized ccRCC. · DOI
  25. Patard, J. J. et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J. Clin. Oncol. 22, 3316–3322 (2004). · DOI
  26. Wolff, I. et al. Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database. Eur. J. Surg. Oncol. 42, 744–750 (2016). · DOI
  27. Meskawi, M. et al. A review of integrated staging systems for renal cell carcinoma. Eur. Urol. 62, 303–314 (2012). · DOI
  28. Motzer, R. J., Hutson, T. E., McCann, L., Deen, K. & Choueiri, T. K. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N. Engl. J. Med. 370, 1769–1770 (2014). · DOI
  29. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015). · DOI
  30. Global Burden of Disease Cancer Collaboration et al. The Global Burden of Cancer 2013. JAMA Oncol. 1, 505–527 (2015). · DOI
  31. Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49, 1374–1403 (2013). · DOI
  32. Shuch, B. et al. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J. Clin. Oncol. 32, 431–437 (2014). · DOI
  33. Nielsen, S. M. et al. Von Hippel–Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome. J. Clin. Oncol. 34, 2172–2181 (2016). · DOI
  34. Haas, N. B. & Nathanson, K. L. Hereditary kidney cancer syndromes. Adv. Chronic Kidney Dis. 21, 81–90 (2014). · DOI
  35. Adeniran, A. J., Shuch, B. & Humphrey, P. A. Hereditary renal cell carcinoma syndromes: clinical, pathologic, and genetic features. Am. J. Surg. Pathol. 39, e1–e18 (2015). · DOI
  36. Znaor, A., Lortet-Tieulent, J., Laversanne, M., Jemal, A. & Bray, F. International variations and trends in renal cell carcinoma incidence and mortality. Eur. Urol. 67, 519–530 (2015). · DOI
  37. Sun, M. et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur. Urol. 59, 135–141 (2011). · DOI
  38. Hakimi, A. A. et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J. Natl Cancer Inst. 105, 1862–1870 (2013). · DOI
  39. McLaughlin, J., Lipworth, L., Tarone, R. & Blot, W. in Cancer Epidemiology and Prevention (eds Schottenfeld, D. & Fraumeni, J. F. ) 1087–1100 (Oxford Univ. Press, 2006). · DOI
  40. Benichou, J., Chow, W. H., McLaughlin, J. K., Mandel, J. S. & Fraumeni, J. F. Jr. Population attributable risk of renal cell cancer in Minnesota. Am. J. Epidemiol. 148, 424–430 (1998). · DOI
  41. Chow, W. H., Dong, L. M. & Devesa, S. S. Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol. 7, 245–257 (2010). · DOI
  42. Faramawi, M. F., Johnson, E., Fry, M. W., Sall, M. & Zhou, Y. Consumption of different types of meat and the risk of renal cancer: meta-analysis of case–control studies. Cancer Causes Control 18, 125–133 (2007). · DOI
  43. Lee, J. E. et al. Fat, protein, and meat consumption and renal cell cancer risk: a pooled analysis of 13 prospective studies. J. Natl Cancer Inst. 100, 1695–1706 (2008). · DOI
  44. Setiawan, V. W., Stram, D. O., Nomura, A. M., Kolonel, L. N. & Henderson, B. E. Risk factors for renal cell cancer: the multiethnic cohort. Am. J. Epidemiol. 166, 932–940 (2007). · DOI
  45. Tavani, A. et al. Lifetime physical activity and the risk of renal cell cancer. Int. J. Cancer 120, 1977–1980 (2007). · DOI
  46. Bergstrom, A. et al. Physical activity and risk of renal cell cancer. Int. J. Cancer 92, 155–157 (2001). · DOI
  47. Karami, S. et al. Family history of cancer and renal cell cancer risk in Caucasians and African Americans. Br. J. Cancer 102, 1676–1680 (2010). · DOI
  48. Kaelin, W. G. Von Hippel–Lindau disease. Annu. Rev. Pathol. 2, 145–173 (2007). · DOI
  49. Purdue, M. P. et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat. Genet. 43, 60–65 (2011). · DOI
  50. Wu, X. et al. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum. Mol. Genet. 21, 456–462 (2012). · DOI
  51. Henrion, M. et al. Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer. Hum. Mol. Genet. 22, 825–831 (2013). · DOI
  52. Gudmundsson, J. et al. A common variant at 8q24.21 is associated with renal cell cancer. Nat. Commun. 4, 2776 (2013). · DOI
  53. Schodel, J. et al. Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. Nat. Genet. 44, 420–425 (2012). · DOI
  54. Bigot, P. et al. Functional characterization of the 12p12.1 renal cancer-susceptibility locus implicates BHLHE41. Nat. Commun. 7, 12098 (2016). · DOI
  55. Hakimi, A. A., Pham, C. G. & Hsieh, J. J. A clear picture of renal cell carcinoma. Nat. Genet. 45, 849–850 (2013). · DOI
  56. Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277–285 (2010). This paper proposes RCC as a metabolic disease with mutations concentrating on metabolic pathways. · DOI
  57. Masson, N. & Ratcliffe, P. J. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab. 2, 3 (2014). · DOI
  58. Hakimi, A. A. et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 29, 104–116 (2016). This paper reports the largest global metabolomics study of ccRCC and demonstrates its prognostic values. · DOI
  59. Reuter, V. E. & Tickoo, S. K. Differential diagnosis of renal tumours with clear cell histology. Pathology 42, 374–383 (2010). · DOI
  60. Lee, C. H. et al. Bevacizumab monotherapy as salvage therapy for advanced clear cell renal cell carcinoma pretreated with targeted drugs. Clin. Genitourin. Cancer 14, 56–62 (2016). · DOI
  61. Wei, E. Y. & Hsieh, J. J. A river model to map convergent cancer evolution and guide therapy in RCC. Nat. Rev. Urol. 12, 706–712 (2015). This paper proposes a novel cancer evolution model of ccRCC through gene–pathway–phenotype convergence. · DOI
  62. Pena-Llopis, S. et al. BAP1 loss defines a new class of renal cell carcinoma. Nat. Genet. 44, 751–759 (2012). · DOI
  63. Hakimi, A. A. et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur. Urol. 63, 848–854 (2013). · DOI
  64. Sato, Y. et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 45, 860–867 (2013). · DOI
  65. Xu, J. et al. Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. J. Clin. Invest. 126, 3526–3540 (2016). · DOI
  66. Grabiner, B. C. et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 4, 554–563 (2014). Together with reference 73, these two papers demonstrate that activating mutations in MTOR are common genetic events in ccRCC. · DOI
  67. Voss, M. H. et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin. Cancer Res. 20, 1955–1964 (2014). This paper demonstrates the association between mutations in the core mTORC1-regulatory pathway and long-term therapeutic benefit from rapalogues. · DOI
  68. Kwiatkowski, D. J. et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 22, 2445–2452 (2016). · DOI
  69. Hakimi, A. A. et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA Research Network. Clin. Cancer Res. 19, 3259–3267 (2013). · DOI
  70. Kapur, P. et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 14, 159–167 (2013). Together with reference 77, these two papers demonstrate the prognostic values of PBRM1, BAP1 and SETD2 mutations in ccRCC. · DOI
  71. Nam, S. J., Lee, C., Park, J. H. & Moon, K. C. Decreased PBRM1 expression predicts unfavorable prognosis in patients with clear cell renal cell carcinoma. Urol. Oncol. 33, 340.e9–340.e16 (2015). · DOI
  72. Manley, B. J. et al. Integration of recurrent somatic mutations with clinical outcomes: a pooled analysis of 1049 patients with clear cell renal cell carcinoma. Eur. Urol. Focushttp://dx.doi.org/10.1016/j.euf.2016.06.015 (2016). · DOI
  73. Venkatesan, S. & Swanton, C. Tumor evolutionary principles: how intratumor heterogeneity influences cancer treatment and outcome. Am. Soc. Clin. Oncol. 35, e141–e149 (2016).
  74. Kanu, N. et al. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene 34, 5699–5708 (2015). · DOI
  75. Gulati, S. et al. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. Eur. Urol. 66, 936–948 (2014). · DOI
  76. Beuselinck, B. et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin. Cancer Res. 21, 1329–1339 (2015). · DOI
  77. Brooks, S. A. et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur. Urol. 66, 77–84 (2014). · DOI
  78. Senbabaoglu, Y. et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 17, 231 (2016). · DOI
  79. Geissler, K. et al. Immune signature of tumor infiltrating immune cells in renal cancer. Oncoimmunology 4, e985082 (2015). · DOI
  80. Sinha, R. et al. Evaluating renal cell carcinoma cell lines as tumor models. Nat. Commun. (in press). This paper presents the most comprehensive in silico analysis of publically available RCC cell lines.
  81. Winter, S. et al. Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. Sci. Rep. 6, 29930 (2016). · DOI
  82. Huang, D. et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 70, 1053–1062 (2010). This paper provides clear evidence that sunitinib acts primarily on the tumour endothelium using cancer cell lines. · DOI
  83. Huang, D. et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70, 1063–1071 (2010). · DOI
  84. Zhou, L. et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 35, 2687–2697 (2016). · DOI
  85. Dong, Y. et al. Development of a clear cell renal cell carcinoma xenograft model: a case for the use of biopsy tissue over surgical tissue. J. Urol. 195, e916 (2016). Using patient-derived xenograft ccRCC models and tumour cells from patients with known primary response or resistance to sunitinib, this paper confirms that the principal therapeutic effect derived from sunitinib is through targeting tumour blood vessels. · DOI
  86. Wang, S. S. et al. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. Proc. Natl Acad. Sci. USA 111, 16538–16543 (2014). · DOI
  87. Palapattu, G. S., Kristo, B. & Rajfer, J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev. Urol. 4, 163–170 (2002).
  88. Low, G., Huang, G., Fu, W., Moloo, Z. & Girgis, S. Review of renal cell carcinoma and its common subtypes in radiology. World J. Radiol. 8, 484–500 (2016). · DOI
  89. Karlo, C. A. et al. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology 270, 464–471 (2014). This is the first radiogenomics study of ccRCC. · DOI
  90. Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P. & Mazumdar, M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289–296 (2002). This paper presents the value of Memorial Sloan Kettering Cancer Center risk factors in stratifying patients with metastatic kidney cancer. · DOI
  91. Heng, D. Y. et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 14, 141–148 (2013). · DOI
  92. Linehan, W. M., Srinivasan, R. & Garcia, J. A. Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. Semin. Oncol. 40, 511–520 (2013). · DOI
  93. Marconi, L. et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur. Urol. 69, 660–673 (2016). · DOI
  94. Tickoo, S. K. & Reuter, V. E. Differential diagnosis of renal tumors with papillary architecture. Adv. Anat. Pathol. 18, 120–132 (2011). · DOI
  95. Moch, H. An overview of renal cell cancer: pathology and genetics. Semin. Cancer Biol. 23, 3–9 (2013). · DOI
  96. Algaba, F. et al. Current pathology keys of renal cell carcinoma. Eur. Urol. 60, 634–643 (2011). · DOI
  97. Fuhrman, S. A., Lasky, L. C. & Limas, C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am. J. Surg. Pathol. 6, 655–663 (1982). This paper reports and establishes the nuclear grading of RCC. · DOI
  98. Cheville, J. C., Blute, M. L., Zincke, H., Lohse, C. M. & Weaver, A. L. Stage pT1 conventional (clear cell) renal cell carcinmoa: pathological features associated with cancer specific survival. J. Urol. 166, 453–456 (2001). · DOI
  99. Grignon, D. J. & Che, M. Clear cell renal cell carcinoma. Clin. Lab. Med. 25, 305–316 (2005). · DOI
  100. de Peralta-Venturina, M. et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am. J. Surg. Pathol. 25, 275–284 (2001). · DOI
  101. Bi, M. et al. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc. Natl Acad. Sci. USA 113, 2170–2175 (2016). · DOI
  102. Malouf, G. G. et al. Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations. Eur. Urol. 70, 348–357 (2016). · DOI
  103. Manley, B. J. & Hsieh, J. J. Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components. Transl Cancer Res. 5, S160–S165 (2016). · DOI
  104. Thompson, I. M. The evaluation of microscopic hematuria: a population-based study. J. Urol. 138, 1189–1190 (1987). · DOI
  105. Zhang, L. et al. iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell renal cell carcinoma. Biosci. Trends 10, 210–219 (2016). · DOI
  106. Morrissey, J. J. et al. Evaluation of urine aquaporin-1 and perilipin-2 concentrations as biomarkers to screen for renal cell carcinoma: a prospective cohort study. JAMA Oncol. 1, 204–212 (2015). · DOI
  107. Tosaka, A. et al. Incidence and properties of renal masses and asymptomatic renal cell carcinoma detected by abdominal ultrasonography. J. Urol. 144, 1097–1099 (1990). · DOI
  108. Gudbjartsson, T. et al. A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int. J. Cancer 100, 476–479 (2002). · DOI
  109. Hunt, J. D., van der Hel, O. L., McMillan, G. P., Boffetta, P. & Brennan, P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int. J. Cancer 114, 101–108 (2005). · DOI
  110. Theis, R. P., Dolwick Grieb, S. M., Burr, D., Siddiqui, T. & Asal, N. R. Smoking, environmental tobacco smoke, and risk of renal cell cancer: a population-based case–control study. BMC Cancer 8, 387 (2008). · DOI
  111. Adams, K. F. et al. Body size and renal cell cancer incidence in a large US cohort study. Am. J. Epidemiol. 168, 268–277 (2008). · DOI
  112. Luo, J. et al. Body size, weight cycling, and risk of renal cell carcinoma among postmenopausal women: the Women's Health Initiative (United States). Am. J. Epidemiol. 166, 752–759 (2007). · DOI
  113. Albiges, L. et al. Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J. Clin. Oncol. 34, 3655–3663 (2016). · DOI
  114. Chow, W. H., Gridley, G., Fraumeni, J. F. Jr & Jarvholm, B. Obesity, hypertension, and the risk of kidney cancer in men. N. Engl. J. Med. 343, 1305–1311 (2000). · DOI
  115. Gago-Dominguez, M., Yuan, J. M., Castelao, J. E., Ross, R. K. & Yu, M. C. Regular use of analgesics is a risk factor for renal cell carcinoma. Br. J. Cancer 81, 542–548 (1999). · DOI
  116. McCredie, M., Stewart, J. H. & Day, N. E. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int. J. Cancer 53, 245–249 (1993). · DOI
  117. Dhote, R., Thiounn, N., Debre, B. & Vidal-Trecan, G. Risk factors for adult renal cell carcinoma. Urol. Clin. North Am. 31, 237–247 (2004). · DOI
  118. Khurana, V., Caldito, G. & Ankem, M. Statins might reduce risk of renal cell carcinoma in humans: case–control study of 500,000 veterans. Urology 71, 118–122 (2008). · DOI
  119. Stewart-Merrill, S. B. et al. Oncologic surveillance after surgical resection for renal cell carcinoma: a novel risk-based approach. J. Clin. Oncol. 33, 4151–4157 (2015). · DOI
  120. Ravaud, A. et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N. Engl. J. Med. 375, 2246–2254 (2016). · DOI
  121. Haas, N. B. et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387, 2008–2016 (2016). · DOI
  122. Negrier, S. et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. Ann. Oncol. 13, 1460–1468 (2002). · DOI
  123. Heng, D. Y. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27, 5794–5799 (2009). · DOI
  124. Bex, A., Ljungberg, B., van Poppel, H., Powles, T. & European Association of Urology. The role of cytoreductive nephrectomy: European Association of Urology recommendations in 2016. Eur. Urol. 70, 901–905 (2016). · DOI
  125. Huang, W. C. et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 7, 735–740 (2006). This paper reports on the increased incidence of chronic kidney disease, leading to the ensuing trials comparing radical and partial nephrectomy in RCC. · DOI
  126. Scosyrev, E., Messing, E. M., Sylvester, R., Campbell, S. & Van Poppel, H. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur. Urol. 65, 372–377 (2014). · DOI
  127. Pignot, G. et al. Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4- cm cutoff. Urol. Oncol. 32, 1024–1030 (2014). · DOI
  128. Van Poppel, H. et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur. Urol. 59, 543–552 (2011). This is the first randomized phase III trial comparing the oncological outcome between partial and radical nephrectomy. · DOI
  129. MacLennan, S. et al. Systematic review of oncological outcomes following surgical management of localised renal cancer. Eur. Urol. 61, 972–993 (2012). · DOI
  130. Weight, C. J. et al. Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. Eur. Urol. 58, 293–298 (2010). · DOI
  131. Sun, M. et al. A non-cancer-related survival benefit is associated with partial nephrectomy. Eur. Urol. 61, 725–731 (2012). · DOI
  132. Klatte, T. et al. A literature review of renal surgical anatomy and surgical strategies for partial nephrectomy. Eur. Urol. 68, 980–992 (2015). · DOI
  133. Crestani, A. et al. Introduction to small renal tumours and prognostic indicators. Int. J. Surg. 36, 495–503 (2016). · DOI
  134. Aboumarzouk, O. M. et al. Robotic versus laparoscopic partial nephrectomy: a systematic review and meta-analysis. Eur. Urol. 62, 1023–1033 (2012). · DOI
  135. Zhang, X. et al. Comparison of peri-operative outcomes of robot-assisted versus laparoscopic partial nephrectomy: a meta-analysis. BJU Int. 112, 1133–1142 (2013). · DOI
  136. Ficarra, V. et al. A multicentre matched-pair analysis comparing robot-assisted versus open partial nephrectomy. BJU Int. 113, 936–941 (2014). · DOI
  137. Wu, Z. et al. Robotic versus open partial nephrectomy: a systematic review and meta-analysis. PLoS ONE 9, e94878 (2014). · DOI
  138. Marszalek, M. et al. Positive surgical margins after nephron-sparing surgery. Eur. Urol. 61, 757–763 (2012). · DOI
  139. MacLennan, S. et al. Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. Eur. Urol. 62, 1097–1117 (2012). · DOI
  140. Blom, J. H. et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur. Urol. 55, 28–34 (2009). · DOI
  141. Hanna, N. et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a National Cancer Data Base study. J. Clin. Oncol. 34, 3267–3275 (2016). · DOI
  142. Lane, B. R., Tobert, C. M. & Riedinger, C. B. Growth kinetics and active surveillance for small renal masses. Curr. Opin. Urol. 22, 353–359 (2012). · DOI
  143. Campbell, S. C. et al. Guideline for management of the clinical T1 renal mass. J. Urol. 182, 1271–1279 (2009). · DOI
  144. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007). This pivotal trial led to the approval of the first anti-VEGFR targeted therapy sorafenib for metastatic ccRCC. · DOI
  145. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007). This pivotal trial establishes sunitinib as the first-line treatment for ccRCC, which greatly improved the survival outcome. · DOI
  146. Motzer, R. J., McCann, L. & Deen, K. Pazopanib versus sunitinib in renal cancer. N. Engl. J. Med. 369, 1970 (2013). · DOI
  147. Rini, B. I. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378, 1931–1939 (2011). · DOI
  148. Motzer, R. J. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 16, 1473–1482 (2015). · DOI
  149. Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1814–1823 (2015). · DOI
  150. Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103–2111 (2007). · DOI
  151. Rini, B. I. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26, 5422–5428 (2008). · DOI
  152. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456 (2008). · DOI · Paper page
  153. Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007). · DOI
  154. McDermott, D. F. et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133–141 (2005). This paper reports on a randomized phase III trial, which demonstrated a 23% response rate for high-dose IL-2. · DOI
  155. Cella, D. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer Treat. Rev. 35, 733–737 (2009). · DOI
  156. Cella, D. et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol. 17, 994–1003 (2016). · DOI
  157. Donskov, F. et al. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. Br. J. Cancer 113, 1571–1580 (2015). · DOI
  158. Funakoshi, T., Lee, C. H. & Hsieh, J. J. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treat. Rev. 40, 533–547 (2014). · DOI
  159. Tran, H. T. et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 13, 827–837 (2012). · DOI
  160. Voss, M. H. et al. Circulating biomarkers and outcome from a randomised phase II trial of sunitinib versus everolimus for patients with metastatic renal cell carcinoma. Br. J. Cancer 114, 642–649 (2016). · DOI
  161. Armstrong, A. J., George, D. J. & Halabi, S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J. Clin. Oncol. 30, 3402–3407 (2012). · DOI
  162. Fay, A. P. et al. Whole-exome sequencing in two extreme phenotypes of response to VEGF-targeted therapies in patients with metastatic clear cell renal cell carcinoma. J. Natl Compr. Canc. Netw. 14, 820–824 (2016). · DOI
  163. Ho, T. H. et al. Correlation between molecular subclassifications of clear cell renal cell carcinoma and targeted therapy response. Eur. Urol. Focus 2, 204–209 (2016). · DOI
  164. Hsieh, J. et al. Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): results from RECORD-3. J. Clin. Oncol. 33, abstr. 4509 (2015). · DOI
  165. Hammers, H. J. et al. Expanded cohort results from CheckMate 016: a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 33, abstr. 4516 (2015). · DOI
  166. Amin, A. et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J. Immunother. Cancer 3, 14 (2015). · DOI · Paper page
  167. Wettersten, H. I. et al. Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis. Cancer Res. 75, 2541–2552 (2015). · DOI
  168. Rodrigues, D. et al. Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems. Transl Res. 180, 1–11 (2017). · DOI
  169. Harding, J. J. et al. Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors. ASCOhttp://meetinglibrary.asco.org/content/109133?media=sl (2015). · DOI
  170. Beatty, G. L. et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. ASCOhttp://meetinglibrary.asco.org/content/83930?media=vm (2013). · DOI
  171. Tartour, E. et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 30, 83–95 (2011). · DOI
  172. Remark, R. et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin. Cancer Res. 19, 4079–4091 (2013). · DOI
  173. Giraldo, N. A. et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. 21, 3031–3040 (2015). · DOI
  174. Demaria, S. et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58, 862–870 (2004). · DOI
  175. Janowitz, T., Welsh, S. J., Zaki, K., Mulders, P. & Eisen, T. Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin. Oncol. 40, 482–491 (2013). · DOI
  176. Bozic, I. et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2, e00747 (2013). · DOI
  177. Molina, A. M. et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 118, 1868–1876 (2012). · DOI
  178. Voss, M. H. et al. Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma. J. Clin. Oncol. 4, 3846–3853 (2016). · DOI
  179. Hsieh, J. J. & Cheng, E. H. A braided cancer river connects tumor heterogeneity and precision medicine. Clin. Transl Med. 5, 42 (2016). · DOI
  180. Powles, T. et al. Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 34, 1660–1668 (2016). · DOI
  181. Carlo, M. I. et al. A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma. Oncologist 21, 787–788 (2016). · DOI
  182. Nakaigawa, N. et al. Inactivation of von Hippel–Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res. 66, 3699–3705 (2006). · DOI
  183. Mizukami, Y. et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med. 11, 992–997 (2005). · DOI
  184. Albiges, L. et al. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur. Urol. 67, 100–110 (2015). · DOI
  185. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016). · DOI · Paper page
  186. Massari, F. et al. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat. Rev. 41, 114–121 (2015). · DOI
  187. Armstrong, A. J. et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 17, 378–388 (2016). · DOI
  188. Tannir, N. M. et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur. Urol. 69, 866–874 (2016). · DOI
  189. Dutcher, J. P. et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med. Oncol. 26, 202–209 (2009). · DOI
  190. Yates, L. R. & Campbell, P. J. Evolution of the cancer genome. Nat. Rev. Genet. 13, 795–806 (2012). · DOI
  191. Shuch, B. et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur. Urol. 67, 85–97 (2015). · DOI
  192. Beaumont, J. L. et al. Patient-reported outcomes in a phase III study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy. Oncologist 16, 632–640 (2011). · DOI
  193. Yang, S., de Souza, P., Alemao, E. & Purvis, J. Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br. J. Cancer 102, 1456–1460 (2010). · DOI

Cited by

Sorted by citations

See all 2,426

Metadata

Authors
Hsieh, J. J., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D. Y., Larkin, J., & Ficarra, V.
Venue
Nature Reviews Disease Primers
Publisher
Springer Science and Business Media LLC
Published
2017-03-09
Volume
3
Issue
1
ISSN
2056-676X
DOI
10.1038/nrdp.2017.9
PMC
PMC5936048
Cited by
2,426
References
16
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review